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Abstract
Hepatitis C Virus (HCV) is a single stranded RNA virus which produces negative strand RNA as a replicative
intermediate. We analyzed 75 RT-PCR studies that tested for negative strand HCV RNA in liver and other human
tissues. 85% of the studies that investigated extrahepatic replication of HCV found one or more samples positive
for replicative RNA. Studies using in situ hybridization, immunofluorescence, immunohistochemistry, and
quasispecies analysis also demonstrated the presence of replicating HCV in various extrahepatic human tissues, and
provide evidence that HCV replicates in macrophages, B cells, T cells, and other extrahepatic tissues. We also
analyzed both short term and long term in vitro systems used to culture HCV. These systems vary in their purposes
and methods, but long term culturing of HCV in B cells, T cells, and other cell types has been used to analyze
replication. It is therefore now possible to study HIV-HCV co-infections and HCV replication in vitro.
Introduction
The majority of the current research on human hepatitis
C virus (HCV) is unusual in that it does not study the
natural virus, but instead studies are based on synthetic
constructs and their manipulations. This article will
limit itself to the analysis of viral RNA and proteins
from patient sera or on replicating virus isolated from
cells infected with HCV from patient sera. HCV is an
old entity, but the bulk of our knowledge is fairly recent.
Human hepatitis B virus (HBV) was identified in the
1960s. The hepatitis cases that could not be identified
either as Hepatitis A or Hepatitis B were referred to as
non-A non-B hepatitis. HCV was molecularly cloned
and identified in the late 1980s [1] and an almost com-
plete sequence was obtained soon thereafter [2]. HCV is
a single stranded, positive sense RNA virus that is vari-
able in size, but approximately 50 to 80 nm in diameter.
It is a member of Hepacivirus group in the family
Flaviviridae.
The HCV genome is about 9.6 kb in length. One large
precursor protein is synthes i z e df r o ma no p e nr e a d i n g
frame of over 9024 nucleotides. This polyprotein is then
cleaved to produce 10 proteins (Figure 1). These include
three structural proteins at the amino end of the RNA
transcript: Core and two envelope proteins (E1 and E2).
An ion channel protein p7 is formed by cleavage of E2
[3]. Next are six proteins that are not in the viral parti-
cle (NS2, NS3, NS4A, NS4B, NS5A, and NS5B). In addi-
tion, a protein called F or ARFP can be produced from
a frame-shift of the Core protein [4]. The viral RNA
contains a 5’ untranslated region (5’UTR), typically 341
nucleotides, that is highly conserved between the virus
s t r a i n s[ 5 ] .T h i sr e g i o nc o n t a i n sa ni n t e r n a lr i b o s o m e
entry site (IRES) for translation. The 3’ end of the virus
contains an untranslated region (3’UTR) that is 200 to
235 nucleotides long. It contains, in order, a variable
region, a poly U/UC stretch, and a highly conserved 98
nucleotide sequence [6].
It is now accepted that HCV is a cause of liver dis-
eases and a number of other lymphoproliferative disor-
ders such as mixed cryoglobulinemia (MC) [7-10] and
Non-Hodgkin’s lymphoma (NHL) [11-14]. Other lym-
phoproliferative disorders may also be associated with
HCV infection [15]. Although the pathogenic process is
not well understood, HCV infection progresses slowly
and often ends in chronic diseases. Over years, chronic
infection may end in fibrosis and cirrhosis. A large
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complications of cirrhosis such as hepatocellular
carcinoma.
Classical thinking was that HCV only infects hepato-
cytes and hence the inflammation of liver. Many studies
of HCV have investigated infection of other cell types
such as peripheral blood mononuclear cells (PBMC). In
fact, evidence has begun to accumulate that liver cells
are only one of the targets of HCV infection. The pre-
vious idea was established due to the identifiable disease
associated with liver. However, viral replication has been
reported in B cells, T cells, monocytes, macrophages,
and other macrophage-like cells such as Kupffer cells
and dendrocytes. The study of HCV has been domi-
nated for many years by molecular approaches directed
towards understanding protein functions that may lead
to therapy or vaccines. Yet the biology of HCV has
unfortunately been largely neglected.
We are reviewing reports of the biology of HCV, as
this area of HCV research is in major need of under-
standing. In particular, studies investigating the in vivo
host range of HCV as well as in vitro culture systems
that can be used to study the biology of this virus will
be discussed.
Sites of HCV replication in vivo
For the in vivo studies outlined below, we have looked
at papers that analyzed the presence of HCV RNA.
HCV is a positive strand RNA virus that replicates
through a negative strand intermediate. Papers that
detected or measured the presence of the negative
strand of HCV by a variety of methods were analyzed,
as were papers that described methods to detect the
non-structural (NS) proteins of HCV, since they are not
found in the virion. If the abstract did not mention
negative strands of HCV or NS proteins, we probably
did not include the study in our analysis, except for the
papers that looked at quasispecies or binding of the
virus.
HCV can bind and enter extrahepatic cells
The information below summarizes a number of studies
that represents binding of selected viral proteins but
they do not address the question of viral entry. One of
the first studies on the subject of HCV in serum was on
virus concentrated by ultracentrifugation, followed by
testing the concentrate for positive and negative strands
[16]. These were tests done on cell free virus, and
RNase and detergent sensitivity were tested. Positive
strands were resistant to both RNase and detergents,
while negative strands were resistant to either RNase or
detergent. The investigators concluded that positive
strands were probably protected in an enveloped core,
while negative strands were membrane protected but
not in a protein core.
For replication to occur, HCV must bind and enter
cells like any other virus. Although there has been
extensive study of the receptors that HCV uses to enter
cells, almost all of these have been in vitro studies using
model systems [17]. One HCV binding study investi-
gated the types of HCV in blood [18]. They found that
about 1% of HCV was in cells and 4 to 5% of the virus
was not cell bound and existed in immune complexes.
The binding of free virus to Molt-4 (T cells) and U937
(monocytes) cell lines could be saturated, but binding to
platelets could not. The binding to the cell lines was
inhibited by anti-HCV IgG, with the inhibition exhibit-
ing different kinetics for Molt-4, U937, and platelets.
This suggests that HCV binds to different cell types
using a combination of receptors. Immune complexes
that contain HCV bound Molt-4 and U937 to lesser
extents, but platelets bound free virus or virus particles
in complexes in equal proportions.
HCV replication can be studied by examining particu-
lar steps in the replication process of the virus. One
study analyzed binding of a soluble version of HCV E2
(sE2) to cell types separated from PBMC, including
monocytes, monocyte-derived dendritic cells (mDC),
plasmacytoid dendritic cells (pDC), natural killer cells
( N K ) ,Bc e l l s ,C D 4
+ T cells, and CD8
+ T cells [19]. sE2
binding largely paralleled CD81 expression. However,
monocytes, DCs, and B cells also had CD81 independent
binding. They also found variability in binding efficiency
from different HCV sE2 variants. Another study used
flow cytometry and antibodies against Core and E1 to
study binding and entry into peripheral blood leukocytes
(PBL) [20]. They found that after 1 hour, staining was
found on the surface of the cells, but after 24 hours,
there was no surface staining and 28% of the cells were
intracellularly stained. Negative strand HCV RNA could
be seen at 24 hours post-infection (PI). A study of the
attachment of HCV to Daudi cells (B cells) used RT-
PCR to measure HCV bound or inside cells [21]. They
found that immunocomplexed HCV did not attach as
well as the free virus. The attachment was best at pH
7.0, and HCV then probably entered cells after 90 min-
utes post-infection.
Since much of the HCV in serum is complexed with
antibodies, one study investigated infection of monocytic
Figure 1 Genome organization of HCV.
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and Jurkat) cell lines [22]. They stimulated these cell
lines with phorbal myristate (PMA) and interferon-g to
stimulate Fc receptor expression before infecting with
immune complexes of HCV. Entry was measured by
RT-PCR. Non-stimulated cells showed no viral entry,
while HCV negative strand was detected for up to 7
days after infection in monocytic cells. Little or no bind-
ing was seen for the lymphocytic cell lines. In the
monocytic cell lines, monoclonal antibodies to FcgRII, a
low affinity immunoglobulin G receptor, abolished bind-
ing by immune complexes, suggesting that HCV can
enter cells that express Fc receptors.
Overall, there is strong evidence that HCV can bind
and enter various cell types found outside the liver, and
the process of infection can be studied in vitro [23]. B
cells may preferentially bind free virus, while monocytes
may preferentially bind virus-antibody complexes.
Detection of extrahepatic HCV replication by PCR
PCR is a very sensitive technique for detecting small
amounts of nucleic acids. For detecting HCV, the viral
RNA is converted to DNA by Reverse transcriptase
(RT), and then nested PCR is usually used to amplify
particular regions of the genome. The two most com-
monly amplified regions are the 5’UTR and the hyper-
variable region 1 (HVR1). The 5’UTR is a highly
conserved region that is involved in viral replication and
translation [5], while the HVR1 codes for the amino end
of the envelope protein E2. E2 is involved in binding of
HCV to host cells [24]. Replication of HCV involves
converting the viral genomic positive strand into an
antigenomic negative strand, and then back to the geno-
mic strand. Thus, the presence of the negative strand
strongly suggests that replication is occurring.
We have only analyzed studies that reported RT-PCR
of negative strands of HCV in humans. Many other stu-
dies have investigated positive strands, but the presence
of positive strands is not an evidence of replication
unless other data is presented that can only be found in
cells replicating HCV. Some of those studies will be dis-
cussed in later sections. A number of studies have used
model systems such as Chimpanzees and mice for analy-
sis of HCV replication. We have not analyzed these stu-
dies, as they are model systems that have not proven
useful for studying extrahepatic replication of HCV in
humans.
Initial results with PCR
The initial attempt to measure HCV replication in sera
and livers of patients chronically infected with HCV
found negative strands in most of the serum and liver
samples [25]. Others followed by investigating the types
of infected cells in serum. PBMC was found to contain
negative strand HCV RNA by many investigators
(Table 1), causing others to investigate infection of par-
ticular cell types in PBMC as well as various other
Table 1 HCV negative strand RNA detection by regular RT-PCR in chronic HCV-infected individuals
Patients, Special groups Results for negative strand by PCR Ratio of +/- strands References
HCC 5/5 L, 0/5 S 1 to 100 L [26]
Hemophilia 14/27 P, 20/27 PBMC [148]
Hemophilia 14/19 S, 14/14 PBMC [149]
HIV-HCV co-infected 4/6 PBMC, 0/6 P 8-50 PBMC [150]
IFN a-treated 3/11 P untreated; 1/11 treated PBMC [151]
IFN a-treated 10/10 untreated; 7/9 nonresponders, 2/6 responders PBMC [152]
Mixed cryoglobulinemia 4/6 PBMC, 5/7 BM [153]
NHL 6/8 B [154]
Normal livers 4/4 L, 4/4 PBMC [155]
Oral lichen planus, oral cancer 3/19 Oral lichen planus; 5/7 Oral cancer [74]
Chronic 0/5 S, 1/5 PBMC [156]
Chronic 7/13 PBMC untreated, 5/8 PBMC treated [157]
Chronic 15/15 L, 0/13 P, 2/3 PBMC, 5/9 BM [158]
Chronic 0/3 S, 3/3 PBML [159]
Chronic L, PBML, B positive (no numbers); Not T, NK [160]
Chronic 8/9 L, 5/9 S 10-1000 L; 1-10 S [25]
Chronic 0/19 PBMC, M, T, NK; 3/19 B, 3/19 DC [73]
Chronic 1/1 L, 10/11 S [161]
Chronic 28/51 B, 0/14 T, 1/24 M, 19/47 PML [162]
Chronic 3/5 S, 5/5 PBMC, 3/3 B, 3/3 T, 2/3 M [163]
Key: L = Liver; S = Serum; P = Plasma; B = B cells; T = T cells; M = Monocytes/Macrophages; BM = Bone marrow cells; DC = Dendritic cells; PBML = Peripheral
blood mononuclear lymphocytes; PMNG = Polymorphonuclear granulocytes; PML = Polymorphonuclear leukocytes;
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phages, B cells, and, in one case, T cells were all found
to contain negative strands of HCV. Bone marrow cells
(BMC) and oral tissues were also found to contain nega-
tive strands. For liver [25,26] and serum [25] the ratio of
positive to negative strands were estimated to be
between 1 and 1000 using semi-quantitative PCR.
Problems with regular PCR
In 1994, the possibility of false positive results for ampli-
fying the negative strand was suggested [27]. It is prob-
ably due to self-priming of the RNA or priming by
fragments of RNA or DNA present in the reaction. Var-
ious improvements to the RT-PCR were tested, such as
extended inactivation of RT using heat or Proteinase K,
RNase H removal of RNA, and dilution of RT. These
modifications reduced the chance of false positives. The
use of tagged primers for the RT step also reduced the
incidence of false positives [28]. Tagged primers have
additional sequence on the 5’e n dt h a ti sn o tr e l a t e dt o
the entity being amplified. Another modification to
reduce false positives is the use of rTth polymerase [28].
This enzyme works at a higher temperature (70-74 °C),
and hence produced a significant reduction in false posi-
tives. Therefore, it should be noted that the PCR results
d e s c r i b e da b o v et h a tu s e ds t a n d a r dp r o t o c o l sm a yh a v e
had false positives.
Improved PCR methods for the detection of HCV replication
After 1994, most researchers have followed the recom-
mendations on how to improve RT-PCR to reduce the
chance of false positives when measuring the presence
of negative strands of HCV. Table 2 shows the results of
23 studies that used one or more of the improvements
described above. Again, almost all studies reported find-
ing negative strands of HCV in total PBMC as well as B
cells, T cells, monocytes/macrophages, and other cell
types.
The best method for detecting negative strands of
HCV uses the enzyme rTth DNA polymerase. Table 3
shows results from 30 studies using rTth to analyze
negative strands in various tissues and cell types. HCV
negative strands were again usually found in PBMC, as
well as in B cells, T cells, macrophages/monocytes,
BMC, and other cell types and tissues.
We have quantified the number of studies reporting
HCV replication in a variety of ways (Table 4). First, we
determined the number of studies that found at least
one extrahepatic site containing negative strands. Sec-
ond, we counted the numbers of studies that found any
site, including livers, containing negative strands. Third,
we determined how many results from particular tissues
contained negative strands. Lastly, we determined how
many extrahepatic sites contained negative strands. For
the last two, we counted each tissue or cell type tested
in each study. Unexpectedly, all three categories of PCR
methods appear to give about the same results, and all
agree that negative strands of HCV are found in extra-
hepatic tissues.
Estimated ratios of positive to negative HCV strands
A number of studies have measured the ratio of positive
to negative strands of HCV (Tables 1 to 3). The num-
bers were determined for liver cells, serum, PBMC, and
other cell types. The values range between 1 and 1000,
with most studies determining the ratio to be from 10
to 100. Most of these studies were performed before
real time PCR became common, so they used semi-
quantitative methods that involved diluting samples in
10-fold increments until no band could be detected.
Ten of the 22 studies only measured the ratio in livers,
four compared liver and other tissues, and the other
eight measured only extrahepatic tissues. These num-
bers do not seem to vary with the RT-PCR method.
Conclusions from PCR results
Analyses of the results from RT-PCR studies show that
70% or more of the cell types or tissues that were inves-
tigated were positive for negative strands of HCV (Table
4). In other words, HCV replicates in extrahepatic sites.
If most of the studies showed extrahepatic replication,
why has it not been accepted? One reason may be that
the level of negative strands in cells may be too low to
be considered a reliable detection. As described above,
studies have estimated that the ratio of positive to nega-
tive HCV RNA strands is between 10 to100. In addition,
the levels of positive strand in extrahepatic tissues has
been estimated to be about one-tenth that of the levels
in the liver [25,29]. Therefore, there are probably 100 to
1000 fold higher concentrations of positive strand in
livers than negative strand in extrahepatic tissues.
Another source of inconsistent results is the patient
populations. Studies that showed extrahepatic negative
strands usually did not find them in all patients. How-
ever, determining why negative strands could not be
consistently found is difficult. One study looked at
mother to child transmission of HCV, and found that
mothers with detectable negative strands in PBMC were
more likely to transmit HCV to their child than those
without detectable negative strands [30]. This effect may
be due to concentration differences, but may be due to
other undetermined factors.As t u d yo fH C V - p o s i t i v e
intravenous drug users (IDU) showed that they were
more likely to have negative strand in PBMC than non-
IDU HCV-positive patients [31]. This was most likely
due to the state of their immune systems, but could be
due to other factors such as time after infection. Both
these and other studies suggest that negative strand is
found in PBMC at varying levels, thereby affecting likeli-
hood of detection.
Occult HCV infection is the presence of liver disease
with undetectable or nearly undetectable HCV levels in
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to demonstrate low levels of HCV present in infected
patients [32], while another study demonstrated the pre-
sence of HCV in occult infections by using ultracentrifu-
gation to concentrate HCV [33]. For occult infections,
detection of positive strands is difficult and thus detec-
tion of negative strands would presumably be even more
difficult.
One other problem is that although livers are primar-
ily composed of hepatocytes, they also contain large
numbers of Kupffer cells (macrophages), sinusoid cells
(endothelial), and other cell types in this portal system.
The liver studies using PCR did not distinguish the
contribution of different infected cell types to the result.
Although liver cells always tested positive for the nega-
tive strand of HCV, none of the studies determined
which liver cell type, hepatocytes, Kupffer, sinusoidal
cells, or other cell types, harbored replicating HCV.
One last factor that may have affected this analysis is
publication bias. If researchers did not find extrahepatic
replication, they may not have published their results.
This would cause an overestimate of the studies that
found extrahepatic replication. Although it is likely
there was some publication bias, we are unable to deter-
mine how much of this occurred. This bias would affect
the proportion of studies finding extrahepatic replication
Table 2 HCV negative strand RNA detection by corrected RT-PCR in chronic HCV-infected individuals
Patients, Special
groups
Corrections to regular
PCR
Results for negative strand by PCR Ratio of +/-
strands
References
Acute, chronic RNase A Chronic: 6/12 PBMC; Incubation and acute 0 PBMC
(no + or - strands)
[164]
Acute, chronic, IFN
a-treated
Heat for 30 min, Core 14/35 chronic PBMC, 1/19 acute PBMC [165]
Different genotypes Core 3/11 PBMC, 3/10 CD15+ granulocytes; [166]
1/10 CD14+ M, 2/9 CD19+ B, 0/7 CD3+ T
IFN a-treated Heat 60 min Untreated 0/18 S, 13/15 PBML; treated 0/7 S, 3/3 PBML [167]
IFN a-treated Heat 30 min Untreated: 16/17 L, 5/14 S, 7/13 PBMC; [168]
Treated, Nonresponders 9/10 L, 3/15 S, 3/7 PBMC
LT Heat 1 hr, Core, 3 RT
tested
16/20 L, 0/32 S, 2/26 PBMC, 0/6 BM 10 to 100 PBMC [96]
LT Core and tag 5/5 L 3 to 340 L [95]
Mothers Heat 60 min, RNase,
low RT
5/13 PBMC that transmitted to child; 0/13 that didn’t
transmit HCV
[30]
Occult Heat 30 min 2/5 PBMC [169]
Peripheral neuropathy Tag 0/9 muscle, 0/3 nerve [170]
Chronic Chemically modify
3’ of RNA
9/10 L, 5/10 S, 1/10 PBMC [171]
Chronic Heat 2 hr, RNase H 0/106 P; 33/83 PBMC (40%) [172]
Chronic Heat 98 2 hr 0/7 P, 3/7 PBMC 1 to 100 PBMC [173]
Chronic Core, RNase, Heat
> 20 min
4/8 PBMC [174]
Chronic Core and tag 8/10 L, 0/65 S or P, 1/30 PBMC, 0/12 LT PBMC [175]
Chronic Tag L 2/2, 1/6 P, 1/6 DC, 0/6 CD4+, CD8+, CD14+ M, CD19+ B 300-600 L [176]
Chronic Tag 29/29 S, 11/29 PBMC, 6/29 PMNG [177]
Chronic Tag 3/3 L, 0/3 S 100 L [178]
Chronic Heat 45 min 43/45 L, 0/45 S, 37/45 PBMC [179]
Chronic Tag, RNase A, RNase H 1/1 L 60 L [180]
Chronic NS5 Chronic: 8/8 UTr, 1/3 Tr PBMC; Resolved: 1/10 UTr, 1/1 Tr
PBMC;
up to 1000 [58]
Chronic: 6/8 UTr, 3/4 Tr CD4+ T; 6/8 UTr, 1/7 Tr CD8+ T;
Resolved: 6/10 Tr CD4+ T; 1/3 UTr, 2/4 Tr CD8+ T;
Chronic: 3/4 UTr B; 3/4 UTr M; Resolved: 4/5 UTr B; 2/3 UTr
M
Chronic Heat 30 min 13/33 S [16]
Chronic Heat 30 min 9/9 L, 0/9 S, 0/9 PBMC [181]
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dies using PCR found negative strands in extrahepatic
tissues, even if there was a lot of publication bias, the
published studies would still provide very strong evi-
dence for extrahepatic replication.
Detection of extrahepatic HCV replication by other
methods
As RT-PCR has established that HCV negative strands
are found in various tissues and cell types, we now
examine other evidence that HCV replicates in extrahe-
patic tissues. In addition, some of the techniques
described below have been used to determine the per-
centages of infected cells and/or intracellular locations
of HCV.
Detection of HCV RNA using in situ hybridization
In situ hybridization (ISH) can be used to detect viral
nucleic acids, and can often distinguish infected cell
types, and it can also determine where in the cell the
nucleic acid is located. Although the technique can pro-
vide nice data when it works, there are a number of
problems with the technique. The biggest problem for
detecting HCV replication is the low levels of HCV in
tissues, as ISH may be three orders of magnitude less
sensitive than RT-PCR [34]. In addition, the detection of
negative strands is more difficult due to its lower con-
centration than positive strands. A second problem with
detecting negative strands is that the presence of both
positive and negative HCV RNA in cells can cause them
to form double strands. This makes it harder to detect
Table 3 HCV negative strand RNA detection by rTth RT-PCR in chronic HCV-infected individuals
Patients, special group Results for negative strand by PCR Ratio of +/-
strands
References
Cadavers 0/6 S, 1/4 lymph; 3/6 CNS 10 CNS to 100 S [84]
Co-infected, cadavers 7/8 L, 5/8 lymph, 5/8 pancreas, 2/8 adrenal & thyroid, 1/8 BM & spleen 10-100 Various [29]
Co-infected 15/20 PBMC [45]
Co-infected 0/10 S, 6/10 PBMC, 4/10 M, 2/10 CD4+ & CD8+ T cells, 1/10 CD19+ B, 2/6 M
cultured
10-100 Various [70]
Co-infected women 13/47 S, 17/48 PBMC [104]
Co-infected women 61/144 PBMC; 78/315 total specimens [182]
HCV recovered 9 of 12 PBMC (mitogen stimulated in vitro) [32]
Humans, Chimps 2/2 S, 0/10 PBMC 10 L; >= 1000 S [183]
Ischemic heart disease 8/10 Carotid plaque [184]
Lichen planus 3/3 Skin [185]
Lichen planus/MC+Cutaneous
Vasculitis
0/19 Skin [186]
LT 42/44, as soon as 7 days post-LT [94]
LT 0/9 PBMC before transplantation and 3/9 PBMC after [97]
Lymphoproliferative 4/16 B [187]
Mixed cryoglobulinemia 6/46 PBMC, 5/46 BM [188]
Occult 10/10 L, 5/6 PBMC 1-40 L, 1-2 PBMC [189]
Occult 56/62 L of HCV+ positive, 27/44 L of HCV+ negative [33]
Occult 11/18 PBMC 10-100 PBMC [36]
SVR 15/19 L; 12/13 PBMC 6 PBMC, 2.6 L [57]
Chronic 5/30 in B, 2/30 non-B cells [190]
Chronic 4 of 17 Oral [191]
Chronic 6/6 L, 0/6 S 10-100 L [89]
Chronic 3/3 L 100-1000 L [192]
Chronic 0/47 Leukocyte, 3/3 Liver 41 L [193]
Chronic 2/2 L, HCV-strand declines in concentration with increasing time before
storage
[194]
Chronic 57/61 L 10-1000 L [195]
Chronic 5’UTR, Heat 60 min, RNase: 7/9 PBMC, 0/9 S; rTth: 2/3 L, 0/4 S, 0/4 PBMC [196]
Chronic 4/4 liver, 4/8 PBMC [197]
Chronic 0/33 P, 0/33 PBMC [67]
Chronic 39/48 L 10 L [198]
Key: L = Liver; S = Serum; P = Plasma; B = B cells; T = T cells; M = Monocytes/Macrophages; LT = Liver transplant
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to detect by this method. This problem can be reduced
by denaturing the tissue RNA by heating it to 95°C
before adding the probe. Both of these problems will
cause an underestimation of the number of infected
cells and interfere with determining which cells are
infected. In addition, there is also natural variability
between patients, stage and manifestations of disease,
and tissue types. These and other potential problems
may make it difficult to compare results and sort out
what is actually happening in particular tissues and cells
[35]. We are primarily interested in learning if there are
conclusive evidence for the determination of replication
in particular cell types or tissues.
ISH has been used to study liver cells for evidence of
HCV replication. Fifteen studies listed in Table 5 have
investigated this question. Of these, ten looked at which
cell types were positive for negative strands. Nine stated
that hepatocytes were infected, while nine also men-
tioned infection of other liver cells. Five that mentioned
hepatocytes were infected appeared to assume only
hepatocytes were infected, as they didn’t mention any
other cell types in the liver, infected or not. One study
stated that all the positive cells were not hepatocytes,
while most suggested that other cell types were infected
along with hepatocytes. These studies vary considerably
in their methodologies, patient populations, and results.
However, it appears likely that both hepatocytes and
mononuclear cells harbor replicating HCV in the liver.
In most of these studies, hepatocytes were more likely
to be positive than other cell types.
Studies using ISH also have investigated whether repli-
cation occurs in extrahepatic sites. Five studies were
analyzed to determine whether negative strands could
Table 4 Analysis of RT-PCR studies that detected HCV negative strand RNA.
Studies
Cell types or tissue Regular PCR Corrected PCR rTth PCR Totals
L = liver 6/6 13/13 13/13 32/32
S = serum 3/6 6/11 3/6 12/23
P = plasma 2/4 1/3 0/1 3/8
PBMC 10/11 14/16 12/15 36/42
PBML 3/3 2/2 0/1 5/6
B = B cells/lymphocytes 5/5 3/4 3/3 11/12
T = T cells/lymphocytes 1/4 7/11 2/2 10/17
M = Monocytes/Macrophages 1/2 3/4 2/2 6/8
DC = Dendritic cells 1/1 1/1 2/2
BM = Bone marrow 2/2 0/1 2/2 4/5
Granulocytes, PMNG 2/2 2/2
Oral tissues 3/3 1/1 4/4
Carotid plaque 1/1 1/1
Skin 1/2 1/2
Lymph nodes 2/2 2/2
Pancreas 1/1 1/1
Spleen 1/1 1/1
Thyroid 1/1 1/1
Adrenal 1/1 1/1
CNS, brain, nerve 0/1 1/1 1/2
Muscle 0/1 0/1
NK 0/2 0/2
Total for all tissues 37/47 53/72 47/56 137/175
Percent 78.7 73.6 83.9 78.3
Total extrahepatic tissues 31/41 40/59 34/43 105/143
Percent 75.6 67.8 79.1 73.4
Studies with > = 1 positive result 21/21 22/23 28/30 71/75
Studies with > = 1 positive extrahepatic result 20/21 18/21 19/25 57/67
Data from Tables 1 through 3 have been compiled for numeric comparisons between the three versions of RT-PCR as well as overall results for each tissue
or cell type.
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Page 7 of 25be found in PBMC (Table 5)[36-40]. In all cases, sam-
ples contained negative strands of HCV. Studies also
found replicating HCV in perihepatic lymph nodes
(PLN) [41], salivary gland ductal and acinar epithelial
cells [42,43], and oral epithelial cells [44]. The results,
therefore, suggest that PBMC is likely a site of extrahe-
patic replication. In addition, other tissues are likely
sites of HCV replication.
The ISH studies consistently showed HCV replication
in livers, PBMC, and other tissues. These results agree
with the RT-PCR analyses, but there was no agreement
regarding which cell types in livers harbor replicating
HCV.
Detection of HCV proteins using Immunohistochemistry and
immunofluorescence
Techniques for the analysis of HCV replication also
included the analysis of HCV proteins. As the NS pro-
teins are not found in the virus, evidence that NS pro-
teins are in cells suggests that replication occurred in
those cells. The low concentration of HCV in cells
makes it difficult to detect NS proteins. In addition, NS
proteins may be released from cells and diffuse in the
interstitial space to nearby cells. Lastly, due to the varia-
bility of different isolates of HCV, antibodies may react
against a particular NS protein in cells from one patient
but not with proteins from another patient due to epi-
tope specificity. This usually causes researchers to test a
v a r i e t yo fa n t i b o d i e st of i n dt h eo n et h e yb e l i e v eg i v e s
the best results. Frozen tissues generally give better
results than formalin-fixed samples. As for ISH,
researchers used a variety of methods and antibodies,
making comparisons difficult. We were again interested
in consistent results from various tissues or cell types.
Studies on liver cells using immunohistochemistry
(IHC) or immunofluorescence (IF) for the detection of
NS proteins were evaluated, and eight are listed in
Table 6. Studies that investigated which cells contain
replicating HCV in livers have yielded inconsistent
results. Two studies found only hepatocytes stained
positive for HCV NS proteins, although one didn’ti n d i -
cate whether they investigated other cell types. Four stu-
dies found both hepatocytes and lymphocytes or
Table 5 Analysis of HCV infection by in situ hybridization in chronic HCV-infected individuals
Patients, special groups HCV region of
genome
Results for negative strand References
Co-infected 5’UTR-core-E1 42/63 liver; Some only hepatocytes, some (portal) monocytes/
sinusoidal/biliary
[55]
End-stage liver disease 5’UTR-core-E1 10/20 perihepatic lymph nodes [41]
HCC 5’UTR, core, NS4B 4/9 HCC hepatocytes; 7/10 Non-HCC [199]
HCC 5’UTR Hepatocytes positive, some mononuclear, no biliary or mesenchymal [200]
LT 5’UTR 2/11 LT patients, 2/11 PBMC, 3/3 mitogen stimulated PBMC [40]
MC 5’UTR, core 12/12 hepatocytes [201]
NHL, MC 5’UTR Ductal and acinar salivary epithelial cells [42]
Occult 5’UTR 11/18 PBMC [36]
Oral lichen planus 5’UTR 14/19 oral epithelia [44]
Sjogren’s syndrome or Chronic
sialadenitis
5’UTR 8/8 salivary gland [43]
35% of genome used Hepatocytes not infected-macrophages or lymphocytes; No - strand
detected
[202]
SVR 5’UTR 15/19 Liver [57]
Chronic core-E1 8 of 8 hepatocytes [56]
Chronic core-E1 Quantitative image analysis; hepatocytes, some Kuppfer; +/- ratio 3-20 [147]
Chronic 7 regions Some hepatocytes positive for negative strands [203]
Chronic 5’UTR 24/28 liver negative strand; 14/17 PBMC negative strand; [37]
Chronic 5’UTR 9/20 liver-perinuclear in hepatocytes; mononuclear cells had only
positive strands
[204]
Chronic 5’UTR 4 of 11, all HIV co-infected-hepatocytes and mononuclear cells [205]
Chronic NS5 4/10 H nuclei; 6/10 H cytoplasm; 4/10 M; 0/10 Bile duct epithelial [54]
Chronic 5’UTR FISH, positive strands only: 15-70% of liver cells positive, 0.1 to 4%
PBMC positive
[39]
Chronic 5’UTR, core 4/5 liver, 5/20 PBMC, 0/20 BM [38]
Chronic 5’UTR, core, NS4B 4/10 hepatocytes; 2/4 some lymphocytes [206]
Chronic 5’UTR 17/19 hepatocytes [34]
Key: LT = Liver transplant; HCC = hepatocellular carcinoma; MC = mixed cryoglubulinemia; NHL = Non-hodgkin’s lymphoma; SVR = sustained viral response.
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Page 8 of 25monocytes containing HCV NS proteins, one found only
macrophages, and another found lymphocytes contained
them.
T h e r ew e r ea l s oI H Co rI Fs t u d i e st h a ti n v e s t i g a t e d
the replication of HCV in tissues besides the liver. Five
studies on PBMC are listed in Table 6, as well as
another that looked at PBMC constituents. As seen in
the table, studies using anti-NS4B, anti-NS5, and two
using anti-NS4 all showed positive cells in PBMC. An
additional study using a type of flow cytometry called
SUSHI also showed positive results for PBMC [45].
They further separated the cells into subsets based on
CD14 and CD16 expression and found DCs and macro-
phages stained positive by anti-NS5A, while monocytes
did not. One study found monocytes, B cells, and T
cells all infected in PBMC, while T cells in BMC were
also infected [46]. The significance of all these studies is
they agree that PBMC contains replicating HCV. A
study of brain cells using IF found NS5A stained astro-
cytes and microglial cells (macrophages) [47]. Two of
the other studies listed above also found macrophages
staining positive for NS proteins. Studies have also
investigated replication in other cell types. These found
NS proteins in B cells and other cell types found in
lymph nodes [41], and others found intestinal epithelial
cells [48] and kidney cells [49] stained positive for NS
proteins.
The IF and IHC studies consistently showed that
extrahepatic sites contain replicating HCV, including
macrophages, B cells, and T cells. Studies of liver infec-
tions are inconclusive regarding which cell types primar-
ily contain replicating HCV.
Other methods
A variety of other methods have been used to investi-
gate the infection of various tissues and cell types by
HCV. Although they don’t make definitive statements
about which cells are infected by HCV, they broaden
the range of evidence of replication.
PBMC have been investigated as a possible site of
HCV replication by in situ RT-PCR [50]. In this techni-
que, cells were isolated, fixed with formaldehyde, and
permeabilized. RT is performed, and then tagged PCR is
performed using fluorescent primers. They found 12 of
28 PBMC samples positive for negative strand HCV,
with between 0.2 and 8% of the cells testing positive.
Two studies have looked at the kinetics of viral infec-
tion after liver transplantation. The first investigated
levels of HCV after liver transplantation, noting that
Table 6 Detection of HCV proteins in various tissues in chronic HCV-infected individuals
Patients, special
groups
Method Proteins Evidence for NS proteins References
Acute/chronic IF NS3, NS4 NS4 but not NS3 in hepatocytes [207]
Acute/chronic, IFN a-
treated
IF NS5 17/20 PBMC positive for NS5, all in cytoplasm [165]
Co-infected, cadavers IHC NS5A Astrocytes and microglial cells in CNS (macrophages) positive [47]
Co-infected SUSHI NS5A CD14+CD16++ (DC) and CD14++CD16++ (macrophages); not CD14++CD16-
(monocytes)
[45]
Co-infected IHC NS3 Liver: NS3 more associated with replication than core; [55]
End-stage liver disease IHC NS3 NS3 stained lymph nodes-probably B cells, but likely T and other cells [41]
HCC IHC Core, E2, NS4,
NS5
Hepatocytes positive, some mononuclear [200]
HCC/Cardiomyolitis IHC Core, NS4B Core, NS4B-mostly in macrophages [109]
NHL, MC IHC Core, NS4 Core salivary parotid epithelial, none for NS4 [42]
MC IHC Core, NS4 Both liver and skin positive in some samples were positive [208]
MC RIBA
(Ortho)
NS4 17/37 Sera positive for anti-NS4 antibodies [209]
MC IHC Core, E2, NS4,
NS5
3/12 NS4, 5/12 NS5 kidneys; 2/12, 3/12 capillaries; 2/12, 4/12 blood vessels [49]
Chronic IHC NS3, NS5a 3/4 Liver; 4/10 Intestinal with NS3, 3 also with NS5a [48]
Chronic IHC NS4 Hepatocytes, not monocytes, not endothelial, not bile duct epithelium [210]
Chronic IF Core, NS4 4/11 monocytes and B; 3/11 T cells in BM; 1/11 T in PBMC [46]
Chronic IHC NS4 6/14 livers; hepatocytes stained, no mention of non-hepatocytes [206]
Chronic IHC NS4 NS4 mainly in hepatocytes, some Kupffer, bile duct, mononuclear [211]
Chronic IF E2, NS3, NS4
NS5
NS3: mostly CD8+ T, CD20+ B, some CD4+ T. No CD14+ cells found [108]
Chronic Confocal NS5 CD4+, CD8+, B, and M all stained positive (0.02-0.1%) for NS5 [58]
Chronic IHC Core, NS4 9/12 for both Core and NS4 in hepatocytes and some monocytes [201]
Key: HCC = hepatocellular carcinoma; MC = mixed cryoglubulinemia; NHL = Non-hodgkin’s lymphoma. IF = immunofluorescence; IHC = immunohistochemistry.
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increased [51]. They suggested that viral half life was
short, and extrahepatic replication contributed little to
the level of total virus in the serum. This observation
was based primarily on the decline of HCV concentra-
tion for two days. However, they did not consider that
the repopulation of the liver by HCV infected cells
could reduce HCV in the serum, thereby affecting their
conclusions. The second group of researchers noticed
that the kinetics of HCV concentration in the serum
usually exhibited a biphasic curve [52]. This suggested
that there were two viral compartments, each with dif-
ferent replication kinetics. In other words, the kinetics
suggested extrahepatic replication of HCV occurs.
One study investigated the kinetics of disappearance
of HCV RNA from serum and PBMC after pegylated
interferon and ribavirin therapy [53]. They found com-
parable decreases of HCV RNA in both plasma and
PBMC, but in some patients the times of decay in
PBMC were significantly different than in plasma, sug-
gesting there are at least two cell types involved in
replication.
Percentages of cells infected in vivo
IHC, IF, and in situ PCR have all been used to estimate
the percentage of cells that are infected by HCV. In our
case, we were interested in the percentage of cells that
contained replicating HCV. However, only a few papers
have determined these percentages.
ISH of liver cells suggested that 1 to 5% of cells were
positive, including hepatocytes, mononuclear cells, sinu-
soidal, and biliary epithelial cells [54]. One patient had
as much as 20% of the cells positive. Other studies of
liver cells found the percentage of infected cells to be 10
to 50% [55], 14% [56], or 3% [57].
A study of PBMC and BMC by IF produced an esti-
mate that 0.15 to 1% of cells were HCV-infected [46]. In
some samples, up to 4% of cells tested positive by anti-
NS4. Another study of PBMC by ISH measured the
number of infected cells at 3.3% [36]. A study that
investigated infection of different cell types in occult
infections measured the percentage of cells infected in
PBMC by confocal microscopy and found 0.02 to 1% of
the cells infected [58].
These studies show that only a few percent of cells are
infected by HCV. This number varies widely with study
design and cell type, so a more precise number is cur-
rently not available. Occult infections show a much
lower rate of infected cells.
Different cell types could contain different HCV variants
Quasispecies analysis of HCV has been performed by
single-strand conformational polymorphism analysis
(SSCP) and by sequencing variants that have been
cloned. Comparisons between various tissues or cell
types were then performed. The 5’UTR and HVR1 are
the two areas most often examined, although the NS5B
and HVR2 regions have also been analyzed. For SSCP
analysis, researchers usually sequence bands that vary
between tissues. As one band can harbor more than one
variant, these analyses therefore usually underestimate
the variation in samples [59]. It is not clear, however,
whether this problem would alter the overall conclu-
s i o n so ft h es t u d i e sd e s c r i b e db e l o wa st ow h e t h e rd i f -
ferent tissues harbor different major variants.
Several studies have investigated whether liver variants
are the same as other tissues (Table 7a and 7b). Analysis
of the HVR1 of HCV found in liver, plasma, and PBMC
by one study found significant quasispecies differences
between the three tissues [60]. Variants were found in
each of the tissues that weren’t in the other two tissues.
We analyzed eight other studies that determined var-
iants between liver, serum or plasma, PBMC, and some-
times also the PLN. All but one of the studies found
differences between the liver, serum, and PBMC, which
found small differences in the 5’UTR for some of the
patients [61]. In addition, two studies found different
HCV genotypes in some patients between liver, serum
or plasma, and PBMC [62,63]. These studies show that
each of these tissues contain different variants.
We also evaluated 15 studies that analyzed the differ-
ences between serum or plasma, PBMC, and other tis-
sues by sequencing and, sometimes, SSCP (Table 7c).
These studies did not include liver variants. In all cases
compartmentalization between serum or plasma and
PBMC was seen in many or all of the patients analyzed.
Studies noted lower variability in PBMC than in sera
[64,65], that the compartmentalization was stable for
over two years [63], and that for liver transplant recipi-
ents, the more variable of the donor or recipient strains
later became the dominant strain in the transplanted
liver [66]. Others noted patients with different genotypes
in PBMC and plasma [67,68].
Various combinations of tissues have been examined
by a number of researchers (Table 7d). Studies showed
that various extrahepatic tissues each had variants that
were more alike than variants in the other cell types,
suggesting that each cell type has a pool of HCV that
was a little different than the pool in the other cell types
[58,69-74]. Three of the studies noted that different
compartments at times contained different genotypes, as
measured by the INNO-LiPA line probe assay. The
assay uses HCV RT-PCR products to hybridize to
immobilized probes specific for particular genotypes of
HCV [63,67,75,76].
If tissues contain different variants, do these differ-
ences matter? Two studies analyzed 5’UTR variants in
liver, PBMC, and mDC [77,78]. Both studies found
mDC variants differed from liver variants. One of the
studies investigated in vitro translation efficiency of the
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Page 10 of 25Table 7 Quasispecies analyses of HCV in various tissues in chronic HCV-infected individuals
Patients, special groups Cell types investigated Regions studied Methods References
a. Liver, PBMC, other
End-stage liver disease L, S, PBMC, PLN HVR1 Seq [41]
LT L, S, PBMC, PLN HVR1 HMA, Seq [101]
LT L, S, PBMC, PLN HVR1 Seq [66]
IFN a-treated and SVR occult L, S, PBMC 5’UTR Seq [61]
IFN a-treated and SVR occult L, S, PBMC, PLN HVR1 Seq [100]
Chronic L, P, PBMC HVR1 Seq [60]
Chronic L, S, PBMC HVR1 Clonal frequency analysis, Seq [212]
Chronic L, S, PBMC HVR1 Seq [196]
Chronic L, S, P, PBMC, monocytic DC 5’UTR, HVR1 Seq [78]
Chronic L, P, PBMC 5’UTR INNO-LiPA [62]
b. Liver, other
Cadavers L, S, CNS, lymph 5’UTR, HVR1 Seq [79]
Co-infected L, P, CNS 5’UTR, E1 Seq [80]
Chronic L, S 5’UTR, E2-NS2 Seq [86]
Chronic L, S E2-NS2 Seq [87]
Chronic L, S E2-NS2 Seq [88]
Chronic L, P, CNS 5’UTR, E1 Seq [81]
Chronic L, S 5’UTR SSCP, Seq [89]
Chronic L, PBMC, monocytic DC 5’UTR Seq [77]
c. PBMC, other extrahepatic
Co-infected P, PBMC, CSF 5’UTR Seq, INNO-LiPA [75]
Co-infected S, PBMC, M, B, CD4+ T, CD8+ T 5’UTR SSCP, Seq [70]
Co-infected S, PBMC HVR1 Seq [105]
Co-infected women P, PBMC, Genital-cervicovaginal lavage fluid (CVL) 5’UTR SSCP, Seq [90]
LT S, PBMC 5’UTR SSCP, Seq [98]
LT P, PBMC HVR1 Seq [99]
LT S, PBMC 5’UTR SSCP, Seq [213]
LT S, PBMC NS5B Seq [66]
MC P, PBMC, cryoprecipitate 5’UTR, HVR1 Seq [65]
Chronic P, PBMC 5’UTR, NS5B Seq [214]
Chronic P, PBMC 5’UTR, HVR1 Seq [69]
Chronic P, PBMC 5’UTR, NS5B SSCP, Seq, INNO-LiPA [63]
Chronic S, PBMC, CSF 5’UTR SSCP, Seq [82]
Chronic P, PBMC 5’UTR SSCP, Seq [67]
Chronic S, PBMC HVR1,2+ Seq [64]
d. Other extrahepatic
Cadavers S, CNS (brain autopsies) 5’UTR SSCP, Seq [84]
Co-infected S, CSF 5’UTR, HVR1 SSCP [83]
Co-infected women P, Genital-cervical cytobrush 5’UTR, HVR1 Seq [91]
Co-infected men P, Semen HVR1 Seq [92]
LT S, Brain 5’UTR SSCP, Seq [85]
Oral lichen planus, oral cancer Oral lichen planus, oral cancer 5’UTR, HVR1 Seq [74]
Chronic S, peripheral blood DC HVR1 Seq [72]
Chronic P, BMC 5’UTR SSCP, Seq, INNO-LiPA [76]
Chronic P, B, M, T HVR1 Seq [71]
Chronic P, peripheral blood DC HVR1 Seq [73]
Chronic P, M, B, CD4+ T, CD8+ T 5’UTR Seq [58]
Key: L = Liver; S = Serum; P = Plasma; B = B cells; T = T cells; M = Monocytes/Macrophages; DC = Dendritic cells; CSF = cerebral spinal fluid;
PLN = perihepatic lymph nodes; LT = Liver transplant; MC = mixed cryoglubulinemia; SSCP = single-strand conformational polymorphism; HMA = heteroduplex
mobility;
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Page 11 of 25variants, and mDC variants showed reduced translation
compared to the liver variants. A study that investigated
liver and serum variants in lymphocytes and central ner-
vous system tissues found 24-55% of the 5’UTR variants
absent from serum, while brain and lymph node variants
were more similar than either was to liver or serum var-
iants [79]. To determine if different variants affected
replication of HCV, quasispecies from brain, serum, and
liver were analyzed for in vitro translation efficiency.
T h e yf o u n dt h a tb r a i nd e r i v e dv a r i a n t sw e r et r a n s l a t e d
less efficiently than serum or liver. These studies there-
fore suggest that the quasispecies differences can affect
translation efficiency, and presumably other aspects of
HCV replication.
Since HCV infection is associated with dementia,
investigators have also examined infection of nervous
system tissues. Two studies investigated sequences in
liver, plasma, and brain and found minor differences in
the 5’UTR and major differences in the E1 region
[80,81]. Brain specific sequences were identified. Two
other studies looked at cerebral spinal fluid (CSF) and
found different variants than serum in some patients
[75,82], while a third, using SSCP, found CSF and
plasma very similar [83]. Since SSCP isn’t as sensitive as
sequencing for detecting differences and only three
patients were studied, it is unclear whether this study
could have detected significant differences between
these two tissues. In two related studies, brain tissue
was compared to serum sequences by SSCP and sequen-
cing from tissue obtained from cadavers [84,85]. Brain
and serum variants were significantly different. These
studies suggest that various CNS tissues can harbor var-
iants of HCV not found in liver, plasma, or serum.
The kinetics of HCV infection of tissues has also been
investigated. Studies investigating the quasispecies in
liver and serum found that some patients had signifi-
cantly different quasispecies in the two samples, includ-
ing the consensus sequences [86,87], but that the
quasispecies complexity varied considerably over time
[88]. Variants seemed to appear first in liver, then
spread to serum, suggesting most originated in the liver
and not in the serum. However, the study could not
answer which cells in the liver produce most of the
HCV. One study which compared positive and negative
strand liver variants and serum variants by SSCP and
sequencing showed that four of the patients’ liver nega-
tive strand variants and serum variants were very simi-
lar, while the other two patients had low titers of virus
and unreliable results [89]. As the liver positive and
negative strand variants differed significantly, it may be
that most of the HCV RNA found in the liver may be
inside cells but not replicating. As there is 10 to 100
times as much positive as negative strand in the liver,
most of the virus could be in cells that don’t
productively replicate HCV, while it does replicate in
another cell type. Nevertheless, this needs further study.
Cervicovaginal lavage fluid (CVL) has also been found
t oh a v ev a r i a n t ss i m i l a rt oP B M Co rs e r u mi nH I V -
HCV co-infected women, but not in HCV mono-
infected women [90]. This suggests that HIV facilitates
HCV infection of this tissue. A second study of HIV-
HCV co-infected women compared cervical cytobrush
and plasma and found unique variants in each tissue
[91]. A similar study of HIV-HCV co-infected men
showed the presence of HCV in semen [92]. These
results suggest that infection by HIV can affect which
tissues harbor HCV.
Overall, we analyzed 44 studies, with 43 showing dis-
tinct differences between variants found in two or more
tissues in many of the patients examined. Some also
showed different genotypes in different tissues. One pos-
sibility is that these tissues bind and take in different
HCV variants, but the virus doesn’t replicate in these
tissues or cell types. However, the evidence presented
above for HCV replication in the same types of tissues,
including PCR, viral kinetics, ISH, and IF, leaves little
doubt that HCV replicates in a variety of extrahepatic
sites and in various cell types.
Temporal quasispecies variation during HCV infection
Since different tissues contain different quasispecies, stu-
dies have investigated how these populations change
over time. A recent study followed quasispecies found in
four patients over a span of up to 18 years [93]. They
suggested there were four stages of HCV evolution: (1)
HCV establishes an infection; (2) incremental evolution
of variants within subpopulations; (3) diversification into
new subpopulations; and (4) strong negative selection in
these subpopulations reduces variation and HCV
achieves a stable adaptation to the host. Although the
small number of patients in the study was a drawback,
the model needs further investigation.
A different method of studying temporal variation is
to study the repopulation of livers after transplantation.
HCV from the cells in the serum, including monocytes/
macrophages and lymphocytes, enter and populate
transplanted liver tissue, and free virus in the blood also
infects livers. We examined four studies that used RT-
PCR to examine HCV infection after liver transplanta-
tion. Liver specimens had detectable amounts of nega-
tive strands by RT-PCR within 7 days after
transplantation [94]. Levels of negative strand in the
liver after transplants do not correlate with serum levels
of HCV [94,95], and negative strands were more likely
to be found in transplanted PBMC than in PBMC from
individuals with chronic HCV infection [40,96].
We also examined seven studies that compared qua-
sispecies before and after liver transplantation. These
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mined which type was present in the livers of transplant
recipients at various times after transplantation. Studies
of liver re-infection by HCV have examined the donor
and recipient strains to analyze this process. One early
study showed that initially after one transplantation,
both the donor and recipient HCV strains could be
found in PBMC, but only the recipient strain was found
in serum [97], and, after a week, only the recipient
strain was still found in both serum and PBMC. This
suggested that one strain can take over the infection in
an individual. Another comparison of variants with
those found in the new livers showed that, for 3 of the
4 patients, liver variants were most similar to those
found in serum [98], while another study compared var-
iants in plasma and PBMC after transplantation and
found frequent compartmentalization and a decrease in
quasispecies complexity, which suggests a genetic bottle-
neck [99]. Two studies of liver re-infection compared
donor and recipient HCV strains over time to show that
one strain can overtake or exclude another [66,100],
with the more variable strain at the time of transplant
overtaking the other strain. A study by another group
reached the same conclusions: the most variable strain
(s) at the time of transplant was the one that was pre-
sent much later [101]. Overall, the data suggests that
newly transplanted livers are infected by free virus or
cells from the blood. The strain of HCV with the most
variants is more likely to be able to adapt to the new
liver and outcompetes the other strain. How one strain
out competes another is unknown.
In vitro translation studies
The IRES of HCV, in the 5’UTR, can be used to mea-
sure in vitro translation efficiency by using a bicistronic
r e p o r t e rv e c t o r .T h ev e c t o rc a nt h e nb eu s e di na nin
vitro system or inserted into cells using transfection.
Luciferase is produced by translation of the reporter
vector, so increased luminescence results from increased
translation of the reporter gene.
One study analyzed in vitro translation of HCV var-
iants found in serum [102]. The variants had different
efficiencies for in vitro translation and also after trans-
fection into Vero (monkey kidney), HepG2 (liver carci-
noma), and Jurkat (T cells). Some of the variants
translated better in HepG2 and Vero cells, others in Jur-
kat cells, suggesting that some variants were better
adapted to particular cell types.
As B cells have frequently been found to be infected
by HCV, one group investigated the in vitro translation
efficiency of variants found in B cells and compared
them to variants found in plasma but not B cells [103].
The IRES of HCV variants were tested by bicistronic
dual luciferase expression in Daudi, Raji (B cells), Huh7
(hepatoma), and primary hepatocytes (PCH). They
found plasma IRES were more efficient in Huh7 and
PCH, while the B cell IRES were equally efficient as the
plasma IRES in Raji and Daudi cells.
These studies show that particular variants translate
better in different cell types, supporting the hypothesis
that HCV replicates extrahepatically.
Effect of HIV-HCV co-infection on detection of
extrahepatic replication of HCV
Studies of HCV replication in HIV-HCV co-infected
individuals have been conducted. Although these studies
have been detailed above relating to detection of HCV
and quasispecies analysis, the effects of the co-infection
on HCV replication have not been detailed. Here we
examined two issues: (1) Does HCV replication increase
or decrease in co-infected individuals? (2) Is extrahepa-
tic replication enhanced in co-infected individuals? Only
studies that compared HCV-mono-infected and co-
infected individuals were examined.
Some studies have looked at extrahepatic replication
in co-infected individuals. Three studies investigated the
HCV positive strand load in extrahepatic tissues and
found no significant differences in the average viral load
in either tissue in HCV-infected and co-infected indivi-
duals [83,104] or in the percentage of infected cells [45].
Another study compared HCV-infected and HIV-HCV
co-infected individuals using strand-specific ISH, and
found no correlations with HCV RNA levels [55]. They
did find a correlation of HCV negative-strands in the
liver tissue and disease levels such as liver inflammation
and fibrosis. An early study of HCV quasispecies using
SSCP in CSF of HCV-monoinfected and HIV-HCV co-
infected genotype 1 and 2 individuals showed that both
contained variants similar to plasma [83], while a study
of HVR1 sequences in HCV-monoinfected and co-
infected individuals found higher serum genetic differ-
ences in co-infected individuals [105]. This could be due
to reduced immune pressure on these individuals, or a
greater host range of the virus in co-infected individuals.
However, a different study found reduced quasispecies
heterogeneity in HVR1 as the CD4+ count dropped
[106], which disagrees with the previous study. A recent
study compared patients that responded to HAART
with non-responders and HCV-monoinfected individuals
[107]. There were no significant differences between
HCV-monoinfected and HIV-HCV co-infected indivi-
duals regarding quasispecies heterogeneity, but patients
that responded to HAART showed a ten-fold increase
in evolutionary rates of change of HCV quasispecies
compared to non-responders. They suggested that the
increased heterogeneity may be due to an enlarged viral
replicative space, i.e., an increase in the number of
infectable cells. One last study analyzed cell types for
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found HCV negative strands in PBMC, CD4
+ T cells,
CD8
+ T cells, CD19
+ B cells, monocytes, and macro-
phages [70]. Quasispecies analysis of serum and mono-
cytes/macrophages showed differences, suggesting active
replication in monocytes/macrophages, but they did not
find HCV negative strands in PBMC of HCV mono-
infected individuals. Of the nine studies detailed, three
found no significant differences in RNA loads between
HCV-infected and co-infected individuals, while the
others found differences in quasispecies and/or in which
cells were infected by HCV. Therefore, there do not
appear to be dramatic differences in RNA levels, but co-
infection appears to affect quasispecies and which cell
types are infected by HCV. In particular, HIV may
reduce the number of types of infectable cells available
to HCV.
The effect of co-infection on the CNS has also been
studied. One study of CSF in co-infected individuals
found that of five individuals that had genotype 3a in
serum and PBMC, two had only genotype 1b in CSF,
while two others had a mix of 3a and 1b [75]. Another
study of HCV mono-infected and HIV-HCV co-infected
individuals found 6 of 10 co-infected individuals had
detectable HCV in the brain while only 1 of 3 HCV
mono-infected individuals were positive [80]. Those that
had detectable HCV were more likely to have detectable
HIV levels, and brain HCV sequences did not match
liver or serum. These studies suggest that co-infection
may affect infection of the CNS.
Although the amount of HCV replication in co-
infected individuals may not be significantly different,
most quasispecies analyses showed variants in CSF, gen-
i t a lt r a c t s ,a n dP B M Ct h a ta r en o tp r e s e n ti ns e r u mo r
liver. In addition, co-infected individuals are more likely
to have detectable HCV in extrahepatic tissues. Overall,
it appears that HIV may not affect overall HCV replica-
tion but may affect the range of cell types producing
detectable HCV. HCV infects macrophages and T cells,
which are also infected by HIV. Studies of how these
viruses interact in these cell types will help us under-
stand the interactions between these two viruses.
Conclusions of in vivo studies
We have analyzed studies that have used RT-PCR to
detect negative strands in over a dozen different extra-
hepatic sites. These studies provide overwhelming evi-
dence that HCV negative strands are found outside the
liver. As negative strands are evidence of HCV replica-
tion, by analogy the RT-PCR evidence strongly suggests
HCV replication outside the liver.
Studies that used hybridization or antibody binding
and detection were used to observe replication in indivi-
dual cells. These studies, in theory, can determine
exactly which cells are infected and contain replicating
HCV. Unfortunately, ISH, IF, and IHC give inconsistent
results. Studies using liver biopsies haven’t consistently
found hepatocytes infected, and often find other positive
cell types. The sensitivity of these methods is low, and
the possibility of both false positives and false negatives
are high. The one consistent result from these studies is
that only a small percentage of cells are infected by
HCV in any particular tissue.
Another method of investigating HCV replication is to
sequence and compare HCV found in various tissues or
cell types. The analysis presented above shows rather
conclusively that the sequences found in different tissues
often differ from each other. Although one explanation
is that different tissues bind different variants of HCV,
the combination of the presence of negative strands of
HCV and different sequences in tissues is very strong
evidence that HCV replicates in a variety of tissues and
cell types.
Many papers on HCV state that the evidence for
HCV replication in hepatocytes is overwhelming.
Although hepatocytes are definitely infected by HCV,
we were unable to find significant evidence for replica-
tion in them. All reported studies using RT-PCR
found negative strands of HCV in liver (Table 4).
However, the liver contains Kupffer cells (macro-
phages), B cells, T cells, endothelial cells and others in
addition to hepatocytes. Studies using ISH, IF, and
IHC have had conflicting results regarding which cells
in the liver contain replicating HCV. Most studies
used cell morphology to identify cell types, while only
three studies that we examined used cell markers to
identify infected cells. One used flow cytometry to
identify DCs and monocytes/macrophages in PBMC as
positive for the presence of NS5A [45]. The second
used antibodies to cell receptors to determine which
cells were infected in livers [108]. Most HCV-infected
cells were CD8
+ T cells or CD20
+ B cells, with few
CD4
+ T cells. The third study used antibodies to
CD68, CD3, and CD20 to stain cells along with anti-
bodies to NS4 [109]. They found CD68 positive cells
contained NS4. Researchers should perform studies
using double-labeling to determine which cell types in
livers contain replicating HCV.
Liver transplants also provide a window into HCV
replication. After liver transplantation, the transplanted
liver is almost immediately repopulated by HCV. Studies
we examined suggested that the variants repopulating
the liver are derived originally from the liver that was in
the individual. However, studies investigating the order
of infection are scant. Which cells are first infected in
the liver? Does the reinfection come from cells in the
blood or from free virus? Answers to these questions
would either confirm or deny the prevailing idea that
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replication.
The significance of extrahepatic replication needs a lot
more study. Some studies have suggested that extrahe-
patic replication occurs, but is of minor significance.
Other studies suggest it has roles in a variety of diseases
associated with HCV infection, including B cell lympho-
mas, hepatocellular carcinoma, and other diseases. A
number of studies have investigated the presence of
negative strands and treatment outcome. One study, for
example, suggested that negative strands in PBMC of
mothers are correlated with transmission to their off-
spring, presumably through the presence of lymphocytes
in breast milk [30]. This needs confirmation and further
study. To fully understand the significance of extrahepa-
tic replication, models must be proposed and in vitro
studies performed.
Which cell types are permissive for HCV
replication in vitro?
Studies analyzing in vitro replication can be broken
down into two major groups: (1) short term cell culture
demonstrating the presence of HCV in particular cell
types and for studies of HCV replication; and (2) long
term cell culture that has the goal of studying all aspects
of HCV. We will look at examples of each type. We can
also break down studies by whether the investigators
cultured infected cells from individuals, or infected fresh
cultured cells with virus fromp a t i e n ts e r u mo rp l a s m a .
Last, studies of infection of various cell types have been
conducted.
There have been numerous reports of in vitro systems,
particularly using cultured hepatocytes. Most of these
haven’t proven useful for further study. Therefore, we
have chosen to only discuss systems that have been
used enough to produce more than one paper, or ones
that illustrate methods or infections of extrahepatic cell
types.
Short term culturing
HCV infection of mixed cell types such as PBMC
One method of studying HCV replication in vitro is to
start with a mixture of cell types found in blood. This
has been done by using PBMC as the host for HCV.
One early study showed that PBMC could sustain an
infection by HCV for about 25 days, with a peak of
infection around the second or third week [110]. Viral
titers were low. Another study infected PBMC stimu-
lated with phytohemagglutinin (PHA) with HCV from
patient plasma and cultured for 15 days [111]. RT-PCR
analysis showed HCV was present, and quasispecies ana-
lysis showed that variants at the end of the culturing
were similar to ones found in patient PBMC. This sug-
gested that the culture mimicked conditions in the
blood. Another study found that lymphoblastic cells
infected with HCV produced three variants in the 5’
UTR [112]. In vitro translation of these variants showed
greater translation in B and T cell lines compared to
HCV strain H77, but not in monocytes or granulocytes.
Another method to study HCV replication is to sepa-
rate the components of PBMC, infect the different cell
types, and determine which cells are positive for HCV.
One study separated PBMC into CD4
+ T cells, CD8
+ T
cells, and CD19
+ B cells [113]. After infecting them and
PBMC, after about two weeks B cells and PBMC con-
tained minus strands, suggesting replication.
Some HCV-infected individuals that have been treated
have undetectable amounts of HCV in the serum and
plasma using standard methods. One method that has
been used to detect HCV in these patients is to culture
patients’ PBMC. In many cases, HCV replicates suffi-
ciently in PBMC to be detectable. One such study inves-
tigated hemophilic patients [114]. They found 5 of 6
PBMC cultures produced HCV. HCV-mono-infected
individuals had PBMC that produced HCV for about 25
days, while HIV-HCV co-infected individuals had PBMC
that produced HCV for around 35 days. They further
investigated this phenomenon and found that PBMC
cultured from co-infected individuals are more likely to
produce HCV than cultures from HCV-mono-infected
individuals [115]. In addition, they isolated B cells trans-
formed by Epstein-Barr virus (EBV) which could con-
tinuously produce HCV for extended periods of time.
HCV infection of lymphoid cells
An early report on HCV infection of T cells used serum
from an HCV-infected Chimpanzee to infect Molt-4
cells [116]. Negative strand HCV was seen from 3 to 7
days PI, and intermittently detected for up to three
weeks in retroviral infected cells. Infection of cells that
were not co-infected was less efficient. Another report
of infection of MT-2 T cells found negative strands at
10 days PI and positive strands for up to 15 days [117],
and they later selected for variants that could be
detected in culture for at least 30 days PI [118]. Testing
of the MT-2 cell line as well as an immortal hepatocyte
cell line called PH5CH showed that culturing HCV iso-
lated from sera affected the variants in HVR1, and the
variants in the two cell lines were different [119]. These
results suggested cell tropism of HCV. Analysis of the
complete genome of the HCV also showed that the cul-
tured HCV became progressively more homogeneous
during the culture period [119].
The first report of in vitro infection of monocytes/
macrophages was using HCV from HIV-HCV co-
infected individuals [70]. The monocytes/macrophages
were purified and cultured in vitro to determine if they
were infectable. Two of seven cultures had negative
strands of HCV for three weeks. One of the two samples
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This suggested that the cells were selecting particular
variants. A following study used fresh macrophages iso-
lated from healthy blood donors for infection by HCV
[120]. They found that 15 of 26 sera from HCV-infected
individuals produced detectable negative strand HCV in
2 to 3 week cultures. Analysis by SSCP and sequencing
of the 5’UTR showed four macrophage cultures had dif-
ferent sequence variants than sera. They also showed
that cell supernatants of HCV-infected cultures had
more IL-8 and TNF-a than uninfected cultures. A third
study by the same group infected fresh macrophages
with HCV and/or M-tropic HIV [121]. All cultures
infected first by M-tropic HIV and then HCV were
HCV positive, while only 3 of the 6 cultures infected
only by HCV were positive. In a similar set of experi-
ments for Daudi cells that expressed CD4, all HIV and
HCV infected cell cultures were positive for HCV, while
5 of 6 infected only with HCV were positive. HIV there-
fore facilitates infection by HCV in macrophages, but
probably not in CD4
+ T cells.
The first in vitro HCV infection of fresh monocytes/
macrophages was performed using cells isolated from
buffy-coats obtained from healthy donors [122]. Nega-
tive strands of HCV were usually found for up to 10
days after infection, while positive strands were found
for up to 27 days. Quasispecies analysis showed that
the complexity of the variants decreased after cultur-
ing, and serum and monocytes/macrophages had dif-
ferent major variants. Since monocytes/macrophages
isolated from blood could be infected by HCV, a fol-
low-up study could find no cytopathic effects or nega-
tive strands in Kupffer cells obtained from liver cancer
patients [123].
Daudi cells have been investigated as a host for HCV
replication. One study showed that HCV in Daudi cells
can be detected for up to 19 days, and the total amount
of HCV increased 30-fold [124]. They found that
enlarged Daudi cells were positive for HCV by ISH.
They also found virus-like particles about 42 nm in size
in the cytoplasm of cells displaying early signs of apop-
tosis. Membrane bound organelles were common, as
were intracytoplasmic electron dense inclusion bodies.
Immature DC and mature DC were investigated as a
target of HCV [125]. HCV positive strand, were detect-
able for up to 10 days PI, while negative strands could
be seen as early as day 2. In mature DC, the positive
strand was detectable for only 5 days PI, and the nega-
tive strands on days 1 and 2 PI. They also compared
quasispecies in the HVR1 of the inoculums and imma-
ture DC positive strands at 6 days PI and found differ-
ences, suggesting selection of particular variants by
immature DC.
Synthetic systems
The first major development of a synthetic model sys-
tem for studying HCV was a Replicon model [126]. A
revised model system was later developed that contained
much more of the genome, and is called JFH-1 [127].
The JFH-1 genome is derived from a patient that had
fulminant hepatitis, so probably is a particularly virulent
strain of HCV. Huh-7.5 hepatoma cells are especially
permissive for JFH-1, but attempts to replicate the HCV
model in monocytes, macrophages, DCs, B cells, and T
cells all failed [128]. This study highlights the problems
in using model systems. Even though a synthetic HCV
system was developed that works in vitro in one particu-
lar type of permissive cell, it doesn’ta p p e a rt om i m i c
HCV in vivo. Huh-7 cells are derived from an individual
with hepatocellular carcinoma, and have a defective HFE
protein [129], which is involved in hemachromatosis,
and a defective Fanconi anemia gene, FANCC [130].
Huh7.5 cells, derived from Huh7 cells, are also defective
in RIG-I [131]. The model systems have been useful for
studying intracellular locations of HCV proteins. They
have also been useful for reverse genetics, where muta-
tions are introduced and the effects analyzed. However,
studies using synthetic model systems should be inter-
preted with caution, as the restricted host range and
unusual nature of the Replicon genome casts doubt on
the applicability of the results.
Long term culturing
Long term culturing of HCV can be accomplished by
isolating already infected cells from HCV-infected
patients. One such B cell line was established from a
patient that had type II mixed cryoglobulinemia (MC)
and non-Hodgkin’s B-cell lymphoma (NHL) [132]. The
cell line, SB, can produce virus that is able to infect
fresh Raji cells (B cells) in vitro. Quasispecies analysis
of the virus in SB showed it had similar variants as
spleen, but were different than serum. They also estab-
lished two cell lines by using HCV-infected PBMC,
and then EBV-immortalized B cells. A follow-up study
used virus produced from SB to infect the T cell lines
Molt-4 and Jurkat in vitro [133]. They could detect
positive and negative strands as well as viral proteins.
The virus in the T cells could be passaged twice, but
not for a third time, suggesting the virus was becoming
inactivated. Another study using SB showed that it
could infect CD4
+ T cells, CD14
+ monocytes/macro-
phages, and CD19
+ B cells [134]. As CD4
+ cells were
the most susceptible to virus produced from SB, they
further analyzed this system. Production of interferon-
g was reduced and CD45RA expression declined, sug-
gesting that Th1 development was interrupted, and
apoptosis increased.
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found to be susceptible to infection by HCV [135]. HCV
could be cultured in these cells for at least 6 months.
TO.FE carries endogenous EBV, so it is an immortal cell
line. The infected cells could produce virus-like particles
in the cytoplasm having a diameter of about 45 nm
[136]. They also found cytopathic effects such as
enlarged cytoplasmic vesicles containing amorphous
particles. The persistently infected TO.FEHCV was also
used as donors of HCV to HepG2 cells in co-culture
[137]. HepG2 are not infectable by free virus, so transfer
was likely from cell-to-cell contact. This study suggests
that HCV may spread into hepatocytes primarily
through cell-to-cell contact instead of infection by free
virus. A following study investigated cell-to-cell trans-
mission of HCV from TO.FEHCV cells to 2.2.15 hepa-
toma cells [138]. HCV could still be detected 120 days
after infection of the 2.2.15 cells, but infections using
free virus could not be detected. Quasispecies analysis
of the HCV after 4 months of culture in B cells showed
variants not seen in the initial serum used to produce
the B cell line. The same group also analyzed infection
of the TO.FE cell line and stained infected cells using
anti-NS3, anti-NS4, and anti-E2. Stain for these proteins
was found in the perinuclear space, the golgi apparatus,
and the endoplasmic reticulum [139].
An in vitro system using PHA-induced T cells has also
been developed [140]. They detected positive strands
and negative strands of HCV, as well as the proteins
NS5A and E2. Virus could be detected for at least 11
days PI, and passaged performed multiple times in T
cells. They later used the system to show that indivi-
duals with sustained virological response (SVR) could
still infect T cells [141]. The infection of T cells was
blocked by anti-E2, anti-CD81, and interferon-a.
Culturing of HCV in PBMC has been performed by
multiple groups, but after about 25 days the HCV titers
drops. This is probably due to changes as the macro-
phages start to mature after about two weeks of culture.
They change from releasing cytokines that promote
other cell types to releasing cytokines that inhibit them
[142]. A novel culture system was therefore developed
to take into account the properties of PBMC and its
components (Figure 2). The system uses HCV from
serum or plasma to infect macrophages. The macro-
phages and other cell types are purified from umbilical
cord blood. After a week of culture, a cell-free extract of
HCV is used to infect other cell types [23]. The virus is
called CIMM-HCV (Figure 3). EBV infected B cells have
been used to culture HCV by this system for over two
years. T cells, neuronal cells, and non-committed lym-
phoid cells can also be infected using this system. Cell
lines selected for permissiveness to HCV were not used
in this system, so the replication of HCV in this system
is likely to be closer to natural replication than the
other systems described above. In addition, it can be
used to study replication in a greater variety of cell
types than the other long term culture systems. Analysis
of the 5’UTR of HCV cultured using this system showed
only minor changes when HCV genotype 1 was cultured
in these cell types [143]. Comparison of sequences of
the 5’UTR for HCV samples containing deletions or
that were genotype 3 provided evidence that cord blood
macrophages select for 5’UTR sequences similar to
HCV genotype 1 [144,145]. As both macrophages and T
cells can be infected by HCV using this system, the sys-
tem has been used to co-infect T cells with HCV, HIV,
and HHV-6 [146]. Cells containing all three viruses
were observed (Figures 4 and 5), demonstrating that this
isolation system can be used to study co-infection by
these three viruses. As noted above, it is unclear how or
whether HIV and HCV interact in vivo,s ot h i ss y s t e m
could provide a method to investigate interactions
between these viruses.
Figure 2 Flow chart for long term in vitro culturing of HCV
isolated from patient serum or plasma. Figure adapted from
reference [23].
Figure 3 Electron micrograph of mature (black arrow) and
immature (red arrow) HCV from in vitro infected T-cell. Picture
adapted from reference [146].
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Short term in vitro systems have been useful for demon-
strating the presence and replication of HCV isolated
from particular tissues or cell types. However, studies of
t h ei n f e c t i o u sp r o c e s sa r eb e s td o n eu s i n gin vitro sys-
tems that can culture HCV for months or years.
We have described above a long term culture system
that isolated infected B cells from one patient. This cul-
ture, SB, produces virus that has been used for several
further studies, and has beenu s e dt oi n f e c to t h e rc e l l
types. The limitation of the system is that there is only
one version of the virus. The second culture system
found a permissive cell type, TO.FE, which is also able
to produce virus for extended periods of time. The virus
produced has been studied as well as transferred to
hepatoma cells. The limitations of this system include
the use of a permissive host and that it is limited to B
cells. It is also unclear if it can be used to reproducibly
isolate HCV from sera or plasma. Culturing of virus
produces variants, and using a cell line that is permis-
sive suggests that it harbors mutations that allow HCV
to grow. The third long term culture system can be
used to infect T cells with HCV. The limitation of this
system is that it only can be used to culture HCV in T
cells. It has not been used to study HIV-HCV co-infec-
tion. The fourth and last long term culture system does
not use cell lines. Instead, the system uses cells purified
from cord blood for the culturing. This has the advan-
tage of using normal cells that are not defective in pre-
venting HCV replication, and it can be used to study
infection of a variety of cell types. However, the disad-
vantage is that additional effort is required to isolate the
cells used in this system. The system may mimic a more
natural infection where HCV passes from one cell type
to another. In addition, its ability to promote the infec-
tion of a wider range of cell types gives the in vitro sys-
tem a unique advantage: it has been demonstrated that
it can be used to study co-infections of HIV, HCV, and/
or HHV-6.
Importance and significance of extrahepatic
infection by HCV
Since little is currently known about HCV replication, it
is essential that studies be performed to try to under-
stand the biology of the virus. We therefore will discuss
some models of how HCV replicates in humans, and
suggest how to test these models.
Model 1: HCV replicates in hepatocytes. The infec-
tious virus is passed to other hepatocytes either through
production of free virus or by cell-to-cell contact. This
model is probably the model favored by most HCV
researchers. The model would claim that extrahepatic
infection is not important and probably a result of varia-
tion of the virus. Another corollary of this model is that
HCV does not replicate in extrahepatic tissues.
T h ee v i d e n c ep r e s e n t e da b o v er e f u t e st h en o t i o nt h a t
HCV doesn’t replicate extrahepatically. However, the
main claim is that HCV replicates from hepatocyte to
hepatocyte. The lack of culture systems for hepatocytes
suggests that this claim is relatively weak. In addition,
evidence that HCV replicates only in hepatocytes is
poor. For this model to be accepted, there would have
to be a preponderance of studies that show that HCV
does not replicate in other liver cell types. Studies have
suggested that infection of livers can occur as foci,
where a clump of cells is infected in one place, another
clump in another place, and so on [147]. What cell
types are in the clump? To date there are contradictory
studies on this. Furthermore, there would have to be a
culture system developed that could take HCV from
serum or plasma and culture it for extended periods of
time. To date neither of these has been accomplished.
One other note is that the current synthetic culture sys-
tem using JFH-1 used sequences from a patient that had
fulminant hepatitis. This suggests that the JFH-1 strain
was derived from a virus that had adapted to primarily
infect hepatocytes, thereby causing fulminant hepatitis.
Most patients do not seem to have an HCV strain
adapted to only infect hepatocytes.
Model 2: HCV infects macrophages, produces free
virus, and transfers it to B cells and hepatocytes. An
example for this model is the role of macrophages in
harboring large intracellular amounts of HIV. This pre-
sumably maintains a reservoir of HIV in vivo, enabling
Figure 4 Example of a triply-infected K7 cell. TEM showing HIV-1
particle budding from the plasma membrane (arrow). Figure from
reference [146].
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types. Similarly, the infection of macrophages could be
from free virus or from virus-antibody complexes.
The method that HCV uses to infect macrophages or
monocytes has not yet been determined. If immune
complexes are the method of infection, then the cells
should use Fc receptors for binding and entry. As noted
above, there has been one study that suggests this
method may be used, but it needs to be repeated by
others. It may be that free virus also infects macro-
phages, and HCV could use two different methods to
infect macrophages. In addition, the receptors for other
cell types also need to be determined. How does HCV
infect B cells? How does it infect T cells? Does the gen-
otype of the virus matter for extrahepatic replication? In
vitro studies described above suggest that HCV genotype
1 preferentially replicates in macrophages. Would this
account for the difficulty of treatment of that genotype?
Model 3: HCV infects lymphoid cells, which pass virus
to hepatocytes, which pass virus to lymphoid cells.
Studies described above suggest lymphoid cells can be
infected by HCV, and can pass the virus to hepatocytes.
The passages could therefore be due from free virus or
cell-to-cell contact. Additional and more definitive stu-
dies of infected cells in the liver would help determine if
HCV replicates in lymphoid cells, macrophages, and/or
hepatocytes in the organ.
We are sure that other models of HCV infection can
be developed and tested. The main issue is that nobody
is developing and testing such models.
Conclusions
Although HCV was identified over 20 years ago, there
are many unanswered questions about this virus. The
major question is the details of the entry and the repli-
cation cycle of HCV. We have presented a large amount
of evidence from a variety of labs using a number of dif-
ferent techniques to address a variety of questions,
including host range and target specificity in terms of
immune reactivity. The in vivo studies described above
Figure 5 Detail from triply-infected cell from Figure 4. (A) HHV-6 shown budding from the nuclear membrane (black arrows) and HCV
located in the perinuclear space (white arrow); (B) HCV particles observed in the cytoplasm; (C) HIV-1 particle located outside the cell. (D) HHV-6
(black arrows) and HCV (white arrow) located in the perinuclear space. Figure from reference [146].
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HCV infects not only hepatocytes, but many other
extrahepatic sites that include B cells, T cells, and
macrophages/monocytes. The life cycle of HCV is
unclear, but may involve cycling between liver and other
tissues. A complex life cycle could help explain why it
takes a long time for HCV-infected individuals to pro-
gress to liver and other diseases. Although they can be
difficult to perform, more in vivo studies that address
the life cycle of HCV are needed, particularly studies of
the infection of livers.
Systems that study the natural virus in vitro need to
be supported and exploited. The infectious process in
macrophages, B cells, T cells, and other cell types need
to be studied to determine if the current knowledge of
infection and spread of HCV in specially engineered
hepatoma cells by synthetic systems is meaningful. Stu-
dies using synthetic model systems have serious pro-
blems which have been largely ignored. The Replicon
studies have avoided and masked the questions related
to the real virus. Now that extrahepatic replication has
been established, studies should be performed to deter-
mine its significance. Even the Replicon related studies
should be focused on non-hepatic cells. This new area
should be considered essential to understanding the life
cycle of HCV, and not an irrelevant adjunct to the cur-
rent mainstream of attention. Another significant area
for investigation is the different genotypes and the
hypervariable regions of the HCV genome.
Overall, there is a great need to be a much broader
understanding of the biology of HCV in addition to col-
lecting proteins for potential therapy.
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